RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Addition of AMPLATZER PFO Occluder to Medical Therapy is Beneficial in Patients with Cryptogenic Stroke and PFO
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 1
SP 18
OP 19
DO 10.1177/155989771301005
UL http://mdc.sagepub.com/content/13/1/18.abstract
AB Cryptogenic stroke remains a major challenge for clinicians taking care of patients who have had strokes. Patent foramen ovale (PFO) is a contributor to cryptogenic stroke due to paradoxical embolism [Furlan AJ et al. N Engl J Med 2012], but the optimal management strategy for PFO has yet to be defined [Kitsios GD et al. Stroke 2012]. This article reports the results of a follow-up analysis of the RESPECT PFO Clinical Trial [RESPECT; NCT00465270] to characterize the qualifying and endpoint ischemic strokes.